<html><body><h2>Case: 1339168</h2><h3> CDS Time: 1974-08-01</h3>
<patient name=1339168>
74.0 year old Black_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">74</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">10</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">90</td><td width="200">1973-3-15</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">87</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Chloride</td><td width="200">103.0</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">94</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">60</td><td width="200">1974-8-1</td></tr>
<tr><td width="200">Weight</td><td width="200">140</td><td width="200">1974-8-1</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">34</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">11</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">11</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">188</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">SGOT</td><td width="200">16</td><td width="200">1973-3-15</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">110</td><td width="200">1974-8-1</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1973-3-15</td></tr>
<tr><td width="200">Height</td><td width="200">66</td><td width="200">1974-8-1</td></tr>
<tr><td width="200">Potassium</td><td width="200">4</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">188</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">BUN</td><td width="200">17</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">HCT</td><td width="200">36</td><td width="200">1972-8-28</td></tr>
<tr><td width="200">HGB</td><td width="200">12</td><td width="200">1972-8-28</td></tr>
<tr><td width="200">Sodium</td><td width="200">141</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1973-3-15</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.2</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">14</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">14</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">Pulse</td><td width="200">100</td><td width="200">1974-8-1</td></tr>
<tr><td width="200">PLT</td><td width="200">209</td><td width="200">1972-8-28</td></tr>
<tr><td width="200">WBC</td><td width="200">8</td><td width="200">1972-8-28</td></tr>
<tr><td width="200">eGFR</td><td width="200">47</td><td width="200">1974-4-25</td></tr>
<tr><td width="200">SGPT</td><td width="200">23</td><td width="200">1973-3-15</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1974-4-8</td></tr>
<tr><td width="200">smoking</td><td width="200"></td><td width="200">1974-1-4</td></tr>
<tr><td width="200">Tobacco_Use</td><td width="200"></td><td width="200">1974-1-4</td></tr>
<tr><td width="200">tobacco use</td><td width="200"></td><td width="200">1974-1-4</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1974-4-8</td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1974-4-8</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1974-4-8</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1974-4-22</td></tr>
<tr><td width="200">Obstructive_Pulmonary_Disease</td><td width="200"></td><td width="200">1974-8-1</td></tr>
<tr><td width="200">Atrial_Tachycardia</td><td width="200"></td><td width="200">1974-1-4</td></tr>
<tr><td width="200">Race</td><td width="200">Black_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> aspirin(1.0) metformin(500.0) simvastatin(20.0) pravastatin(80.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[Presence of CKD (lab or ICD9)]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(110/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(74.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of lipid disorder ICD9]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(47.0/1974-4-25)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(47.0/1974-4-25)]()</td></tr>
<tr><td width="200">No med and K>=3.5</td>
<td width="200"></td>
<td width="200"> 1st line drug for hypertension[Potassium(4.3/1974-4-25) && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(74.0/1970-1-1)]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1974-01-04</td>
<td width="200"> Atrial_Tachycardia()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1974-04-22</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">Psychiatric_Diseases</td>
<td width="200">1974-01-04</td>
<td width="200"> Tobacco_Use()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1974-04-08</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1974-04-08</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Respiratory_Diseases</td>
<td width="200">1974-08-01</td>
<td width="200"> Obstructive_Pulmonary_Disease()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1974-01-04</td>
<td width="200"> tobacco use()
<tr> <td width="200"></td>
<td width="200">1974-01-04</td>
<td width="200"> smoking()
<tr> <td width="200"></td>
<td width="200">1974-04-08</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Not Stage D HF (refractory end stage HF)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage A HF
<b>Scenario choice:</b> Stage C HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(110/null))
<p>
<b>Goal:</b> LDL< 100 mg/dL(CHD Risk Equivalent)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(87.0/1974-4-25))
<p><b>Messages by Types</b>
<ul>
<li><b>Class I</b>
<ul>
<li>Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li>Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li>For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li>Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
</ul>
<li><b>Class III</b>
<ul>
<li>Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to avoid behaviors that may increase the risk of HF (e.g., smoking, excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>Blood sugar control <font color=FF0000>preferred</font></b>(rule in criterion<i> diabetes_mellitus</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])
For patients with diabetes mellitus (who are all at high risk for developing HF), blood sugar should be controlled in accordance with contemporary guidelines. (Level of Evidence: C)
<li><b>Ventricular rate/sinus rhythm  control <font color=FF0000>preferred</font></b>(rule in criterion<i> Presence of supraventricular tachyarrhythmias</i> evaluate to <b> true</b> because <i>Presence of supraventricular tachyarrhythmias</i>)])
Ventricular rate should be controlled or sinus rhythm restored in
patients with supraventricular tachyarrhythmias who are at high
risk for developing HF. (Level of Evidence: B)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b> </b><br>
<ul>
<li><b>stage A drug choices <font color=FF0000>preferred</font></b>(strict rule-in condition<i> DM or HTN or atherosclerotic vascular disease</i> evaluate to <b> true</b> because <i>diabetes_mellitus</i>)])

</ul>
</ul>
<b>Considerations for adding drug: </b><ul><li>Ace_Inhibitor(Captopril, Lisinopril, Enalapril)<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>rec add ace: dose adjustent based on kidney functio(Refer to specific ACE Inhibitor dose adjustments based on kidney function.)<li>monitoring renal function and K(Need to find content)<li>preference: preferred</ul><li>ARB<ul><li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[diabetes_mellitus && Absence of HF]) <li>preference: preferred</ul></ul></body></html>